Comparative efficacy and safety of first-line treatments for advanced hepatocellular carcinoma: a Bayesian network meta-analysis - Takeaways - MDSpire

Comparative efficacy and safety of first-line treatments for advanced hepatocellular carcinoma: a Bayesian network meta-analysis

  • By

  • Yun Su

  • Tongze Cai

  • Jingxuan Wei

  • Qiuju Huang

  • Chun Yao

  • Lei Fu

  • Jinghui Zheng

  • Hongwei Guo

  • Xiongbin Gui

  • June 5, 2026

  • 0 min

Share

  • 1

    A Bayesian network meta-analysis of 16 trials with 8,753 patients evaluated first-line treatments for advanced hepatocellular carcinoma (HCC).

  • 2

    HAIC-based regimens, especially sorafenib plus HAIC, ranked highest for both progression-free survival and overall survival in advanced HCC.

  • 3

    Immunotherapy combinations showed significant survival benefits without increasing severe adverse events across various patient subgroups.

  • 4

    Subgroup analyses indicated consistent treatment benefits across demographics and clinical characteristics in patients with advanced HCC.

  • 5

    Future head-to-head randomized trials are needed to refine optimal treatment strategies for advanced HCC due to evolving evidence and comparator limitations.

Original Source(s)

Comparative efficacy and safety of first-line treatments for advanced hepatocellular carcinoma: a Bayesian network meta-analysis

  • by Yun Su, Tongze Cai, Jingxuan Wei, Qiuju Huang, Chun Yao, Lei Fu, Jinghui Zheng, Hongwei Guo, Xiongbin Gui

  • June 5, 2026

Related Content

Targeted therapy in thyroid cancer: molecular alterations and clinical management

Value of point-of-care ultrasound in the early identification of left ventricular dysfunction and prognostic assessment in cancer patients complicated by sepsis

Multiple primary head and neck cancers: a scenario-based framework for diagnosis and modern multidisciplinary management